Autonomic and Peripheral Neurochemical Responses to Maximal Rowing Exercise
Integrated Autonomic, Neuroendocrine and Peripheral Neurochemical Responses to Maximal Rowing Exercise and Early Recovery in Elite Athletes
The goal of this observational study is to characterize autonomic, neuroendocrine, and peripheral neurochemical responses to maximal rowing exercise and early recovery in highly trained male athletes.
The main questions it aims to answer are:
- How do circulating concentrations of cortisol, testosterone, dopamine, serotonin, gamma-aminobutyric acid (GABA), and the testosterone-to-cortisol ratio change in response to maximal rowing exercise and during the first hour of recovery?
- How do autonomic cardiovascular parameters, including heart rate variability, blood pressure variability, and baroreflex sensitivity, change 3 hours after maximal exercise compared with baseline values?
- Do endocrine, peripheral neurochemical, and autonomic responses demonstrate similar or divergent recovery patterns following maximal exercise?
Participants will:
- Perform a maximal 6,000-m rowing ergometer test.
- Undergo venous blood sampling before exercise, immediately after exercise, and 1 hour after exercise recovery for assessment of endocrine and peripheral neurochemical markers.
- Undergo noninvasive cardiovascular and autonomic assessment using the Task Force Monitor System before exercise and 3 hours after exercise recovery.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This observational study was conducted to investigate physiological responses to maximal rowing exercise and subsequent recovery in highly trained male athletes. The study employed a repeated-measures design, allowing assessment of exercise-induced changes across multiple physiological systems during distinct phases of recovery.
Participants completed a maximal 6,000-m rowing ergometer test under standardized laboratory conditions. Biological and physiological measurements were collected before exercise and during recovery according to a predefined protocol. Venous blood samples were obtained at baseline, immediately after exercise, and after 1 hour of recovery. Noninvasive autonomic and cardiovascular assessments were performed using the Task Force Monitor System before exercise and after 3 hours of recovery. The protocol was designed to capture both immediate biochemical responses and delayed autonomic recovery following maximal exercise.
The study focused on endocrine, peripheral neurochemical, and autonomic cardiovascular regulation. Peripheral neurochemical markers were assessed from blood samples and interpreted as components of the peripheral physiological response to exercise rather than direct indicators of central nervous system activity.
Data collection was performed under controlled laboratory conditions using standardized procedures. All measurements were obtained by trained investigators using calibrated equipment. Data quality was verified through routine review of laboratory and physiological recordings. Implausible values and technical artifacts were identified and evaluated before statistical analysis.
The planned sample size was based on the availability of elite athletes meeting the inclusion criteria and the repeated-measures design of the study. Statistical analyses were conducted using repeated-measures approaches appropriate for longitudinal within-subject data. Data distribution was assessed prior to analysis. Parametric or non-parametric tests were applied as appropriate. Effect sizes were calculated to complement significance testing. Associations between selected physiological variables were explored using correlation analyses. Missing data were handled using complete-case analysis, with no imputation procedures applied.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Poznań
-
Poznan, Poznań, Polonia, 61-871
- Poznań University of Physical Education
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Highly trained rowers competing at the national or international level
- Regular participation in structured rowing training
- Current sports medical clearance for maximal exercise testing
- Ability to complete a maximal 6,000-m rowing ergometer test
- Written informed consent to participate in the study
Exclusion Criteria:
- Acute illness, infection, or injury before testing
- Diagnosed cardiovascular, metabolic, neurological, endocrine, or inflammatory disorder
- Use of medications or supplements that could affect cardiovascular, endocrine, metabolic, or neurochemical responses
- Inability to complete the maximal 6,000-m rowing ergometer test
- Inability or refusal to provide blood samples
- Non-compliance with study procedures or pre-test instructions
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Male elite rowers
|
Participants completed a single maximal 6,000-m rowing ergometer test.
The intervention was distinguished by a standardized all-out rowing protocol combined with peripheral blood sampling before exercise, immediately after exercise, and after 1 hour of recovery, as well as noninvasive autonomic and cardiovascular assessment at baseline and 3 hours after exercise.
|
|
Female elite rowers
|
Participants completed a single maximal 6,000-m rowing ergometer test.
The intervention was distinguished by a standardized all-out rowing protocol combined with peripheral blood sampling before exercise, immediately after exercise, and after 1 hour of recovery, as well as noninvasive autonomic and cardiovascular assessment at baseline and 3 hours after exercise.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from baseline in serum cortisol concentration
Lasso di tempo: Baseline (pre-exercise), 0 minutes post-exercise, and 60 minutes post-exercise.
|
Marker of hypothalamic-pituitary-adrenal axis activation and exercise-induced endocrine response.
|
Baseline (pre-exercise), 0 minutes post-exercise, and 60 minutes post-exercise.
|
|
Change from baseline in serum testosterone concentration
Lasso di tempo: Baseline (pre-exercise), 0 minutes post-exercise, and 60 minutes post-exercise.
|
Marker of anabolic status and exercise-induced endocrine response.
|
Baseline (pre-exercise), 0 minutes post-exercise, and 60 minutes post-exercise.
|
|
Change from baseline in testosterone-to-cortisol ratio (T/C)
Lasso di tempo: Baseline (pre-exercise), 0 minutes post-exercise, and 60 minutes post-exercise.
|
Marker of anabolic-catabolic balance during exercise and recovery.
|
Baseline (pre-exercise), 0 minutes post-exercise, and 60 minutes post-exercise.
|
|
Change from baseline in serum dopamine concentration
Lasso di tempo: Baseline (pre-exercise), 0 minutes post-exercise, and 60 minutes post-exercise.
|
Peripheral neurochemical marker associated with physiological responses to exercise and recovery.
|
Baseline (pre-exercise), 0 minutes post-exercise, and 60 minutes post-exercise.
|
|
Change from baseline in serum serotonin concentration
Lasso di tempo: Baseline (pre-exercise), 0 minutes post-exercise, and 60 minutes post-exercise.
|
Peripheral neurochemical marker associated with exercise-induced physiological responses and recovery processes.
|
Baseline (pre-exercise), 0 minutes post-exercise, and 60 minutes post-exercise.
|
|
Change from baseline in serum gamma-aminobutyric acid (GABA) concentration
Lasso di tempo: Baseline (pre-exercise), 0 minutes post-exercise, and 60 minutes post-exercise.
|
Peripheral neurochemical marker involved in physiological regulatory processes during exercise and recovery.
|
Baseline (pre-exercise), 0 minutes post-exercise, and 60 minutes post-exercise.
|
|
Change from baseline in systolic blood pressure (sBP)
Lasso di tempo: Baseline (pre-exercise) and 180 minutes post-exercise.
|
Continuous beat-to-beat systolic blood pressure measured using the Task Force Monitor System.
|
Baseline (pre-exercise) and 180 minutes post-exercise.
|
|
Change from baseline in diastolic blood pressure (dBP)
Lasso di tempo: Baseline (pre-exercise) and 180 minutes post-exercise.
|
Continuous beat-to-beat diastolic blood pressure measured using the Task Force Monitor System.
|
Baseline (pre-exercise) and 180 minutes post-exercise.
|
|
Change from baseline in mean blood pressure (mBP)
Lasso di tempo: Baseline (pre-exercise) and 180 minutes post-exercise.
|
Continuous beat-to-beat mean arterial pressure measured using the Task Force Monitor System.
|
Baseline (pre-exercise) and 180 minutes post-exercise.
|
|
Change from baseline in heart rate (HR)
Lasso di tempo: Baseline (pre-exercise) and 180 minutes post-exercise.
|
Heart rate derived from continuous electrocardiographic recordings.
|
Baseline (pre-exercise) and 180 minutes post-exercise.
|
|
Change from baseline in total power spectral density of RR intervals (PSD-RRI)
Lasso di tempo: Baseline (pre-exercise) and 180 minutes post-exercise.
|
Total spectral power of heart rate variability obtained from power spectral analysis of RR intervals.
|
Baseline (pre-exercise) and 180 minutes post-exercise.
|
|
Change from baseline in low-frequency power of RR intervals (LF-RRI)
Lasso di tempo: Baseline (pre-exercise) and 180 minutes post-exercise.
|
Low-frequency component of heart rate variability (0.04-0.15 Hz), reflecting combined sympathetic and parasympathetic modulation.
|
Baseline (pre-exercise) and 180 minutes post-exercise.
|
|
Change from baseline in high-frequency power of RR intervals (HF-RRI)
Lasso di tempo: Baseline (pre-exercise) and 180 minutes post-exercise.
|
High-frequency component of heart rate variability (0.17-0.40 Hz), considered an indicator of parasympathetic modulation.
|
Baseline (pre-exercise) and 180 minutes post-exercise.
|
|
Change from baseline in LF/HF ratio
Lasso di tempo: Baseline (pre-exercise) and 180 minutes post-exercise.
|
Ratio of low-frequency to high-frequency spectral power used as an index of sympathovagal balance.
|
Baseline (pre-exercise) and 180 minutes post-exercise.
|
|
Change from baseline in baroreflex sensitivity (BRS)
Lasso di tempo: Baseline (pre-exercise) and 180 minutes post-exercise.
|
Index of baroreflex function calculated using the spontaneous sequence method.
|
Baseline (pre-exercise) and 180 minutes post-exercise.
|
|
Change from baseline in baroreflex effectiveness index (BEI)
Lasso di tempo: Baseline (pre-exercise) and 180 minutes post-exercise.
|
Index quantifying the effectiveness of baroreflex-mediated cardiovascular regulation.
|
Baseline (pre-exercise) and 180 minutes post-exercise.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from baseline in blood lactate concentration
Lasso di tempo: Baseline (pre-exercise), 0 minutes post-exercise, and 60 minutes post-exercise.
|
Marker of metabolic response to maximal rowing exercise and early recovery.
|
Baseline (pre-exercise), 0 minutes post-exercise, and 60 minutes post-exercise.
|
Collaboratori e investigatori
Investigatori
- Cattedra di studio: Anna Skarpańska-Stejnborn, Professor, Poznan University of Physical Education, Gorzów Wielkopolski; Faculty of Sport Sciences in Gorzów Wielkopolski;
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- B-machine
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .